ICN Raises $50 Million
- Share via
COSTA MESA — ICN Pharmaceuticals Inc. said it privately sold $50 million in preferred stock to fund acquisitions in the U.S., Eastern Europe and Asia.
The drug company said the purchases could eventually add more than $150 million in annual sales. Last year, the company posted sales of about $500 million.
The new issue of preferred stock pays a 6% annual dividend in cash or stock, and is convertible into common shares.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
